Compare Toyota Motor Corp (TM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toyota Motor Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Toyota Motor Corp trades at $185.3 (market cap $217.38B), while State Street SPDR S&P Biotech ETF trades at $149.99 (market cap $10.11B). The key difference: Toyota Motor Corp is far larger — about 21.5× State Street SPDR S&P Biotech ETF's market cap, and Toyota Motor Corp pays a 3.37% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toyota Motor Corp for 116 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| TM | XBI | |
|---|---|---|
Market Cap | $217.38B | $10.11B |
Volume | 291,250 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $248.29 | $169.55 |
52-Week Low | $166.50 | $104.99 |
Typical Hold Time | 116 Days | 37 Days |
Enterprise Value | $410.96B | — |
Dividend Yield | 3.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Toyota Motor trades at $182.91, down 1.43% with bearish technical signals despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.38 and P/B of 0.93, while consistently beating earnings expectations in recent quarters. Recent news highlights Toyota's growing U.S. market share and electrification progress with 37.8% growth in EV sales. Cash flow trends show improvement with projected 2026 operating cash flow of $4.13T.
Toyota presents a value opportunity with solid profitability and market positioning, though near-term technical weakness and China sales challenges warrant caution. The company's hybrid technology leadership and North American expansion provide growth catalysts, while analyst consensus leans neutral with 62.5% hold ratings. Debt levels remain manageable at 41.29% debt-to-asset ratio.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
